NO20072048L - Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer. - Google Patents

Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.

Info

Publication number
NO20072048L
NO20072048L NO20072048A NO20072048A NO20072048L NO 20072048 L NO20072048 L NO 20072048L NO 20072048 A NO20072048 A NO 20072048A NO 20072048 A NO20072048 A NO 20072048A NO 20072048 L NO20072048 L NO 20072048L
Authority
NO
Norway
Prior art keywords
prevention
treatment
neurological diseases
diseases
neurological
Prior art date
Application number
NO20072048A
Other languages
English (en)
Inventor
Yves Sagot
Sandrine Pouly
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20072048L publication Critical patent/NO20072048L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

Oppfinnelsen angår anvendelsen av IL-17F, eller en agonist med IL-17F-aktivitet, for behandling eller forebygging av nevrologiske sykdommer.
NO20072048A 2004-09-21 2007-04-20 Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer. NO20072048L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104573 2004-09-21
US63010504P 2004-11-22 2004-11-22
PCT/EP2005/054719 WO2006032673A1 (en) 2004-09-21 2005-09-21 Use of il-17f for the treatment and/or prevention of neurologic diseases

Publications (1)

Publication Number Publication Date
NO20072048L true NO20072048L (no) 2007-05-30

Family

ID=36089871

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072048A NO20072048L (no) 2004-09-21 2007-04-20 Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.

Country Status (11)

Country Link
US (1) US20080286227A1 (no)
EP (1) EP1799248B1 (no)
JP (1) JP2008513415A (no)
AT (1) ATE427754T1 (no)
AU (1) AU2005286474A1 (no)
CA (1) CA2579166A1 (no)
DE (1) DE602005013805D1 (no)
ES (1) ES2324306T3 (no)
IL (1) IL181713A0 (no)
NO (1) NO20072048L (no)
WO (1) WO2006032673A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5795306B2 (ja) * 2009-04-01 2015-10-14 ジェネンテック， インコーポレイテッド インスリン抵抗性疾患の治療
RU2460457C2 (ru) * 2010-10-27 2012-09-10 Общество с ограниченной ответственностью "Центр мануальной медицины" Академия вертебрологии "Радость движения" доктора А.Н. Сухоручко Способ диагностики вертеброгенных болевых синдромов дегенеративно-дистрофических заболеваний позвоночника
CN109659235B (zh) * 2018-12-14 2021-12-03 武汉华星光电半导体显示技术有限公司 Tft的制备方法、tft、阵列基板及显示装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
CA2391374A1 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
IL164214A0 (en) * 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer

Also Published As

Publication number Publication date
AU2005286474A1 (en) 2006-03-30
WO2006032673A1 (en) 2006-03-30
CA2579166A1 (en) 2006-03-30
ES2324306T3 (es) 2009-08-04
DE602005013805D1 (de) 2009-05-20
EP1799248A1 (en) 2007-06-27
EP1799248B1 (en) 2009-04-08
IL181713A0 (en) 2008-03-20
ATE427754T1 (de) 2009-04-15
JP2008513415A (ja) 2008-05-01
US20080286227A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
NO20034056D0 (no) Proliferative sykdommer
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
UA85559C2 (en) Aminobenzophenone compounds
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
WO2002060374A3 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
UA92593C2 (ru) Лечение мастита энрофлоксацином
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
TW200716561A (en) P38 inhibitors and methods of use thereof
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA85187C2 (en) 2-aminobenzoyl derivatives
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE390144T1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application